Marché de la dégénérescence maculaire liée à l’âge (DMLA) au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et perspectives du marché

Le marché de la dégénérescence maculaire liée à l'âge (DMLA) au Moyen-Orient et en Afrique est stimulé par des facteurs tels que l'augmentation de la population gériatrique, l'augmentation de la prévalence de la maladie et l'augmentation de la demande de produits en développement, ainsi que l'augmentation des investissements dans la recherche et le développement, qui conduisent à la croissance du marché. Actuellement, les dépenses de santé ont augmenté dans les pays développés et émergents, ce qui devrait créer un avantage concurrentiel pour les fabricants afin de développer des produits nouveaux et innovants.

La prévalence de la dégénérescence maculaire liée à l'âge devrait augmenter dans les pays développés en raison du vieillissement de la population et de l'augmentation de l'espérance de vie. On estime que près de 60 % des patients souffrent d'une déficience visuelle grave survenant peu après la naissance. Cette maladie entraîne une vision centrale floue dans l'œil du patient. La demande de traitement et de diagnostic de la dégénérescence maculaire liée à l'âge (DMLA) a augmenté davantage dans les pays développés. Cependant, le coût élevé associé au traitement et à la procédure ainsi que les réglementations gouvernementales strictes pour l'approbation des produits devraient entraver la croissance du marché de la dégénérescence maculaire liée à l'âge (DMLA).

Le marché de la dégénérescence maculaire liée à l'âge (DMLA) au Moyen-Orient et en Afrique est favorable et vise à réduire la progression de la maladie. Data Bridge Market Research analyse que le marché de la dégénérescence maculaire liée à l'âge (DMLA) au Moyen-Orient et en Afrique connaîtra un TCAC de 6,0 % au cours de la période de prévision de 2022 à 2029.

Définition du marché

Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Sometimes abnormal new blood vessels grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. Other reasons for the rising of procedures can be defined by the increasing aging people causes and the requirement for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.

The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of the disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth. However, these treatments are expensive and not available to all patients.

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market Dynamics

Drivers

• Rising geriatric population

The world’s geriatric population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in the number of elderly patients due to the rising prevalence of chronic disease. Age is a severe risk factor for any disease progression as age is an essential parameter that affects fundamental biological mechanisms. Therefore, aging is one of the risk factors for the Middle East and Africa incidence of early AMD. Age-related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.

Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process. Thus, the increasing rate of the geriatric population is expected to drive the growth of the Middle East and Africa age-related macular degeneration (AMD) disease market growth.

• Increasing Prevalence of Age-Related Macular Degeneration (AMD) Disease

The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. These countries had reimbursement policies for age-related macular degeneration (AMD) disease market along with that increasing prevalence of genetic diseases.

Thus, it signifies that increasing prevalence of age-related macular degeneration (AMD) disease is expected to drive the Middle East and Africa age-related macular degeneration (AMD) disease market growth.

Opportunity

•  Rising Research and Development 

Research and development is a prerequisite to modifying the treatment intended to treat different kinds of patients. The demand for age-related macular degeneration (AMD) treatment and procedures increasing worldwide involving every country Middle East and Africa. This is why the companies are continuously focusing on research and development in order to achieve success in providing effective treatment to patients and healthcare workers.

The effects can be seen only for individuals in certain ways that include effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and suffering permanent damage.

As the companies are constantly engaged in developmental activities more innovative products are launched in the market. This thus signifies that increasing research and development is expected as an opportunity for the Middle East and Africa age-related macular degeneration (AMD) disease growth. The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the Middle East and Africa age-related macular degeneration (AMD) disease market.

Restraint/Challenge

• High Cost Of Aesthetic Surgical Procedures

The cost of the product plays a major factor in the market. In the age-related macular degeneration (AMD) disease, it is generally observed that they are highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.

Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with age-related macular degeneration (AMD) disease treatment and diagnosis is expected to restrain the Middle East and Africa age-related macular degeneration (AMD) disease market growth.

Recent Developments

• In January 2022, Genentech, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of wet AMD and DME. This will help the company to commercialize the product in the market in the forecast period.
• In April 2022, Graybug Vision Inc. announced that the company has presented a poster presentation preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting for GB-401 in primary open-angle glaucoma (POAG). This will increase the chances for safety and evaluation of drug in the market.

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market Segmentation

Middle East and Africa age-related macular degeneration (AMD) disease market is categorized into is categorized into three notable segments which are based on type, end user and distribution channel. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

• Dry AMD
• Wet AMD

On the basis of type, the Middle East and Africa age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD.

End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Home Healthcare
• Others

On the basis of end user, the Middle East and Africa age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others.

Distribution Channel

• Retail Sales
• Direct Tender

On the basis of distribution channel, the Middle East and Africa age-related macular degeneration (AMD) disease market is segmented into retail sales and direct tender.

Age-Related Macular Degeneration (AMD) Disease Market Regional Analysis/Insights

The age-related macular degeneration (AMD) disease market is analysed and market size insights and trends are provided by type, end user and distribution channel as referenced above.

The countries covered in the age-related macular degeneration (AMD) disease report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa.

South Africa is expected to dominate due to increasing technological advancement in the developing areas.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Analyse du paysage concurrentiel et des parts de marché de la dégénérescence maculaire liée à l'âge (DMLA)

Le paysage concurrentiel du marché de la maladie de dégénérescence maculaire liée à l'âge (DMLA) au Moyen-Orient et en Afrique fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence au Moyen-Orient et en Afrique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché de la maladie de dégénérescence maculaire liée à l'âge (DMLA).

Certains des acteurs du marché sont Novartis AG, Bayer AG, Johnson & Johnson Services, Inc, Adverum Biotechnologies, Inc. entre autres.

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse des parts de marché du Moyen-Orient et de l'Afrique par rapport aux régions et des fournisseurs. Veuillez demander un appel à l'analyste en cas de demande de renseignements supplémentaires.

SKU-68459